Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Alzheimer's drug AL002 safety trial ends early

NCT ID NCT05744401

Disease control Sponsor: Alector Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study was a long-term extension of an earlier trial, testing the safety and tolerability of AL002 in 197 people with early Alzheimer's disease. Participants received the drug by IV infusion. The trial was terminated, meaning it stopped before completion, so the full safety and effectiveness data are not available. The main goal was to monitor side effects, including brain abnormalities like swelling or small bleeds.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AL002 (a drug given by IV infusion)
What this could lead to
If successful, this could help confirm whether AL002 is safe enough to continue testing as a potential treatment for early Alzheimer's disease.
What could go wrong
The trial was terminated early, so results are limited. AL002 is still experimental, and previous studies have not yet proven it slows or stops Alzheimer's. Brain swelling or bleeding (ARIA) are known risks with similar drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

197 people

The number who actually took part.

Started

Jan 2023

Finished

Feb 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Completion of the Planned Treatment Period in the AL002-2 study. * The participant is willing and able to give informed consent. * Study partner who consents to study participation and who cares for/visits the participant at least 10 hours a week Exclusion Criteria: * Participants deemed not able to provide consent or assent by the Investigator or by local regulations. * Participants who were prematurely and permanently discontinued from treatment in the parent study for safety reasons. * Participation deemed inappropriate per Investigator discretion.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer's disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer's disease

Contacts and locations

Locations

  • "Alzheimers Research and Treatment Center-Wellington "

    Wellington, Florida, 33449, United States

  • ASL Biella - Ospedale degli Infermi

    Ponderano, Piedmont, 13875, Italy

  • ASST degli Spedali Civili di Brescia - Spedali Civili di Brescia - INCIPIT - PIN

    Brescia, Lombardy, 25123, Italy

  • Advanced Clinical Institute

    Neptune City, New Jersey, 07753, United States

  • Alfred Health

    Melbourne, Victoria, 3004, Australia

  • Ambulantes Gesundheitszebtrum der Charite GmbH

    Berlin, State of Berlin, 12200, Germany

  • Axiom Brain Health LLC

    Tampa, Florida, 33609, United States

  • Azienda Ospedaliero Universitaria Pisana

    Pisa, Italy

  • Azienda Ospedaliero-Universitaria di Modena - Policlinico di Modena

    Modena, Modena, 41126, Italy

  • Azienda Policlinico Umberto

    Rome, Lazio, 00185, Italy

  • Banner Alzheimer's Institute

    Phoenix, Arizona, 85006, United States

  • Baycrest Health Sciences

    Toronto, Ontario, M6A 2X8, Canada

  • Box Hill Hospital

    Box Hill, Victoria, 3128, Australia

  • Brain Research Center Den Bosch - PPDS

    's-Hertogenbosch, North Brabant, 5223 LA, Netherlands

  • Centro De Atencion Especializada Oroitu

    Getxo, Vizcaya, 48993, Spain

  • Centro de Psiquiatria Biologica

    Mendoza, Mendoza Province, 05500, Argentina

  • Centrum Medyczne NeuroProtect

    Warsaw, Masovian Voivodeship, 01-684, Poland

  • Charité - Universitätsmedizin Berlin

    Berlin, State of Berlin, 13125, Germany

  • Charter Research

    Lady Lake, Florida, 32159, United States

  • Conquest Research LLC - Winter Park - ClinEdge - PPDS

    Winter Park, Florida, 32819, United States

  • EUROMEDIS Sp. z o.o.

    Szczecin, West Pomeranian Voivodeship, 70-111, Poland

  • Feinstein Institute For Medical Research

    Manhasset, New York, 11030, United States

  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico

    Milan, Lombardy, 20122, Italy

  • Fondazione IRCCS Di Rilievo Nazionale Istituto Nazionale Neurologico Carlo Besta-VIA MANGIAGALLI 3

    Milan, Lombardy, 20133, Italy

  • Fondazione Policlinico Universitario A Gemelli-Rome

    Rome, Lazio, 00168, Italy

  • Fundacion ACE Instituto Catalan de Neurociencias-Gran via de Carles III, 85 bis

    Barcelona, Barcelona, 8028, Spain

  • Fundacion CITA Alzheimer Fundazioa

    San Sebastián, Guipúzcoa, 20009, Spain

  • Georgetown University Medical Center

    Washington D.C., District of Columbia, 20007, United States

  • Hattiesburg Clinic

    Hattiesburg, Mississippi, 39401, United States

  • Hospital Universitari i Politecnic La Fe de Valencia

    Valencia, Valencia, 46026, Spain

  • Hospital Universitario Doctor Peset

    Valencia, Valencia, 46017, Spain

  • Hospital Universitario Ramon y Cajal

    Madrid, Madrid, 28034, Spain

  • Hospital Viamed Montecanal

    Zaragoza, Zaragoza, 50012, Spain

  • Hospital de La Santa Creu i Sant Pau

    Barcelona, Barcelona, 08025, Spain

  • IRCCS - Centro S. Giovanni di Dio Fatebene fratelli

    Brescia, Lombardy, 25125, Italy

  • Instituto Privado Kremer

    Córdoba, Córdoba Province, X5004AOA, Argentina

  • K2 Medical Research - Maitland

    Maitland, Florida, 32751, United States

  • KaRa Institute of Neurological Disease

    Macquarie Park, New South Wales, 2113, Australia

  • Kawartha Regional Memory Clinic

    Peterborough, Ontario, K9H 2P4, Canada

  • Klinikum rechts der Isar der Technischen Universitaet Muenchen

    Munich, Bavaria, 81675, Germany

  • NZOZ Wroclawskie Centrum Alzheimerowskie

    Wroclaw, Lower Silesian Voivodeship, 53-110, Poland

  • NeuroClin Glasgow

    Motherwell, ML1 4UF, United Kingdom

  • Ospedale Isola Tiberina - Gemelli Isola

    Rome, Lazio, 00186, Italy

  • Progressive Medical Research - ClinEdge - PPDS

    Port Orange, Florida, 32127, United States

  • RE: Cognition Health - Plymouth

    Plymouth, Devon, PL6 8BT, United Kingdom

  • Re-Cognition Health - Bristol

    Bristol, Bristol, BS32 4SY, United Kingdom

  • Re:Cognition Health

    London, W1G 9RU, United Kingdom

  • Re:Cognition Health - Guildford - PPDS

    Guildford, Surrey, GU2 7YD, United Kingdom

  • SFM Clinical Research, LLC

    Boca Raton, Florida, 33487, United States

  • SUNY Upstate Medical Center

    Syracuse, New York, 13210, United States

  • Summit Research Network

    Portland, Oregon, 97210, United States

  • The National Hospital for Neurology and Neurosurgery

    London, WC1N 3BG, United Kingdom

  • University of Cincinnati Medical Center

    Cincinnati, Ohio, 45219, United States

  • Universitätsklinikum Ulm-Oberer Eselsberg 45

    Ulm, Baden-Wurttemberg, 89081, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.